{"id":"W2988207531","doi":"10.1182/blood-2019-128283","title":"The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; McGill University Health Centre; London Health Sciences Centre; University of Toronto; Western University; Juravinski Cancer Centre; Hôpital de l'Enfant-Jésus; Princess Margaret Cancer Centre; Vancouver General Hospital; University of Calgary; BC Cancer Agency; Alberta Health Services; Alberta Hospital Edmonton; University of British Columbia; Université de Montréal; Hôpital Maisonneuve-Rosemont; CancerCare Manitoba; University of Alberta Hospital; University Health Network; Ottawa Hospital; Dalhousie University","funders":"","keywords":"Discontinuation; Medicine; Dasatinib; Internal medicine; Imatinib; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003179804,0.001270132,0.002017088,0.0003741551,0.001346223,0.001219776,0.001022261,0.001244468,0.003489252],"category_scores_gemma":[0.002425766,0.0003314104,0.002337107,0.00130038,0.001173586,0.0006276142,0.0004973832,0.002141243,0.0004033312],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01033715,"about_ca_system_score_gemma":0.01900079,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.2835675,"about_ca_topic_score_gemma":0.4498109,"domain_scores_codex":[0.997867,0.0004714585,0.00008986494,0.0003248563,0.0006453458,0.0006015647],"domain_scores_gemma":[0.9977786,0.000255834,0.0005213139,0.0001934168,0.0003877535,0.0008630413],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8278162,0.01025724,0.0388911,0.0009132242,0.007218224,0.0002924381,0.0004253072,0.001976128,0.003541262,0.0005712176,0.01355649,0.09454121],"study_design_scores_gemma":[0.3806584,0.1647067,0.4172303,0.0002804448,0.007563852,0.0005466623,0.0003495525,0.001580813,0.001795913,0.0005886633,0.02439641,0.0003022971],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9699677,0.007988949,0.0004761429,0.0009205279,0.000164183,0.002277281,0.009653645,0.00006688675,0.008484778],"genre_scores_gemma":[0.972495,0.002948262,0.001070011,0.0007381004,0.000176259,0.001248031,0.01629798,0.00002217812,0.005004141],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7164325,"threshold_uncertainty_score":0.563834,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0107749785780363,"score_gpt":0.2412208297980505,"score_spread":0.2304458512200142,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}